News and Insights for Psychiatric Pharmacists

Through expert guidance, participants will refine their presentation skills and learn how to captivate audiences. This 2-hour program with ACPE credit provides a unique opportunity to gain practical tools to elevate speaking abilities, enhance your expertise and confidence, and make you a standout voice in the field of psychiatric pharmacy. Don't miss this opportunity to learn!

Toolkit on harm reduction provides tips and guideline summaries in the following areas: consequences of injection drug use, harm reduction services, activities, policies, stigma, potential barriers, professional/policy support, resources, and data sources.

Join us for an industry showcase: Managing Depressive, Acute Manic & Mixed Episodes associated with Bipolar I Disorder In Adults, supported by AbbVie. Registration is free and open to the public!

AAPP and the AAPP Foundation are pleased to be offering a complimentary, 2-hour workshop: Cultivating Expertise: Enhancing Presentation Design and Speaker Development in Psychiatric Pharmacists. Earn ACPE credit and make yourself a standout voice in the field of psychiatric pharmacy!

If you're unable to travel to Seattle for the Annual Meeting, join us virtually to participate in live sessions! Virtual attendees can ask questions and participate during sessions, and all registrants will receive session recordings for all CE sessions. Plan to attend and stay up to date on your education!

Better days start here. #choosepsychpharmacy #pharmd #psychpharm #AAPP

Pharmacy careers change lives. Learn if a job as a pharmacist is right for you and how you can help people live better, healthier lives. #Pharmacy #PsychPharm

Improve your peer review skills! Discover the components to evaluate, the role of the peer reviewer, the skills necessary to critically evaluate a manuscript, and how to provide feedback to authors and journal editors.

Join us for an industry showcase: Challenges in Achieving Symptom Control in Major Depressive Disorder: Considering Adjunctive Treatment Options, supported by Johnson & Johnson. Registration is free and open to the public!

AAPP supports the funding of federal programs directed toward tobacco cessation and outlines specific policy recommendations as to the federal funding programs critical to maintain for individuals living with mental health and/or substance use disorders.

AAPP is a member of a pharmacy‑based vaccine access work group composed of national pharmacy organizations. The work group is conducting a survey to gather insights into vaccination practices since June 2025. Feedback will support pharmacy organizations in their advocacy and education efforts. If applicable to your practice, please complete the survey, available through March 31, 2026.

Pharmacists play a variety of roles in academia: as administrators (e.g., deans, department chairs, etc.), educators, clinical practitioners, and researchers. Often a faculty member plays more than one role, depending on their track (non-tenure versus tenure) and department (pharmaceutical sciences versus pharmacy practice).

This review discusses mechanisms that contribute to negative outcomes after mTBI and hazardous alcohol use and to the development of AUD after mTBI.

The Board of Pharmacy Specialties (BPS) is now accepting applications for the 2027 BPS Ambassador Program. Board-certified pharmacists interested can apply until June 12, 2026.

AAPP supports access to evidence-based monitoring for youth prescribed antipsychotics and updates to child and adolescent psychotropic prescribing regulations.

As part of the planning for the future of DSM, the Biomarkers and Biological Factors Subcommittee of the Future DSM Strategic Committee was empaneled to begin to bridge the gap between psychiatry and neuroscience and move DSM toward a psychiatric nosological system informed by objective measures.

Survey data suggest that prevalence of cigarette smoking among U.S. adults declined 2023 to 2024.

Join us for an industry showcase: The Role of UZEDY in Schizophrenia Treatment: A Clinical Perspective, supported by Teva Pharmaceuticals. Registration is free and open to the public!

Mental health = team sport. #choosepsychpharmacy #pharmd #psychpharm #AAPP

AAPP President Jolene Bostwick talks about the future and our new strategic plan.

This cohort study found that OPC opening was not associated with significant changes in local economic activity.

A meta-analysis of children and teens found social media use was tied to higher rates of depression, behavioral problems, self-injury, and substance use. (JAMA Pediatrics)

Rising temperatures could trigger over a billion additional "symptom-days" of anxiety and depression annually in the U.S., researchers projected. (Lancet Planetary Health)

Genetics play a role in risk of suicide attempt but do not fully explain the sex differences in incidence, a Swedish cohort study found. (BMJ Mental Health)

On March 19 from 4:00-5:30 PM ET NAMI will host this presentation to provide an overview of catatonia and discuss the various potential causes of catatonia, as well as the many different ways in which the syndrome may manifest.

Data suggest that prevalence of cigarette smoking among U.S. adults declined from 10.8% of the population in 2023 to 9.9% in 2024.

MHFA training in pharmacy professionals is an effective intervention to promote mental health support, increase awareness, reduce stigma, and equip participants to make linkages.

Dr. Taylor Nichols, PharmD, BCPP, explains how to embrace harm reduction.

In this cross-sectional study, US adults with IDDs experienced substantially higher rates of mental health conditions, treatment use, and cost-related barriers compared with those without functional impairments.

These resources provide practical toolkits and clinical guidance.

These findings provide a framework for the long-term evaluation of intervention programs and guiding health care resource allocation to reduce adolescent alcohol consumption.

Removal of transmucosal buprenorphine PA requirements for Kentucky Medicaid enrollees was associated with a significant immediate increase in buprenorphine dispensing for OUD treatment.

Emerging evidence suggests novel OAT induction strategies for fentanyl-related OUD are feasible and show a consistent direction toward positive clinical and safety outcomes.

NAMI has relaunched its #Vote4MentalHealth campaign for the 2026 elections. This nonpartisan campaign is part of NAMI’s long-standing efforts to help people across the country understand that voting and mental health are closely intertwined and find the resources and information they need to cast their ballot. NAMI urges voters to take the pledge to #Vote4MentalHealth, which is a commitment to do one thing: understand how your vote impacts mental health. After taking the pledge, people can learn about the issues, share why they #Vote4MentalHealth, register to vote or update their registration, request an absentee ballot, find their polling place and more — all at vote4mentalhealth.org.

Active theta-burst stimulation beat sham stimulation at reducing depression scores by week 12 -- but not by week 6 -- in people with late-life depression, a randomized clinical trial showed. (American Journal of Psychiatry)

While the majority of patients with first-episode psychosis respond to initial treatment with oral risperidone or amisulpride, clozapine appeared to be the best next step for non-responders in a sequential trial. (JAMA Psychiatry)

Stimulant prescriptions for ADHD surged in adults during the COVID pandemic, a Canadian study found. (CMAJ)

The new platform provides for analyzing adverse event reports.

The Stigma Unraveled/Addiction Unmasked interprofessional workshop prompted meaningful and statistically significant changes in participant beliefs, attitudes, behaviors, and knowledge.

Policy interventions and pharmacist advocacy are needed to alleviate challenges.

CPPs provided MOUD care that was safe and effective and outcomes were comparable to physicians and nurse practitioners.

The pharmacist-led intervention more than doubled the pharmacologic treatment rate for AUD in primary care.

A dedicated Pain Management CPS with a focus on addiction medicine provides significant clinical and financial value in the inpatient setting.

This blog series by the Resident and New Practitioner Committee is targeted to psychiatric pharmacists seeking their first or a new position. This blog explores opportunities in the pharmaceutical industry.

This study's findings suggest an association between fluoroquinolones and increased risk of panic attacks.

Join us for an industry showcase: Tardive Dyskinesia: Considerations in the Pharmacy Setting, supported by Teva Pharmaceuticals! Registration is free and open to the public!